Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Research article

Comparing cancer incidence, stage at diagnosis and outcomes of First Nations and all other Manitobans: a retrospective analysis

Authors: Tara C. Horrill, Lindsey Dahl, Esther Sanderson, Garry Munro, Cindy Garson, Carole Taylor, Randy Fransoo, Genevieve Thompson, Catherine Cook, Janice Linton, Annette S. H. Schultz

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Globally, epidemiological evidence suggests cancer incidence and outcomes among Indigenous peoples are a growing concern. Although historically cancer among First Nations (FN) peoples in Canada was relatively unknown, recent epidemiological evidence reveals a widening of cancer related disparities. However evidence at the population level is limited. The aim of this study was to explore cancer incidence, stage at diagnosis, and outcomes among status FN peoples in comparison with all other Manitobans (AOM).

Methods

All cancers diagnosed between April 1, 2004 and March 31, 2011 were linked with the Indian Registry System and five provincial healthcare databases to compare differences in characteristics, cancer incidence, and stage at diagnosis and mortality of the FN and AOM cohorts. Cox proportional hazard regression models were used to examine mortality.

Results

The FN cohort was significantly younger, with higher comorbidities than AOM. A higher proportion of FN people were diagnosed with cancer at stages III (18.7% vs. 15.4%) and IV (22.4% vs. 19.9%). Cancer incidence was significantly lower in the FN cohort, however, there were no significant differences between the two cohorts after adjusting for age, sex, income and area of residence. No significant trends in cancer incidence were identified in either cohort over time. Mortality was generally higher in the FN cohort.

Conclusions

Despite similar cancer incidence, FN peoples in Manitoba experience poorer survival. The underlying causes of these disparities are not yet understood, particularly in relation to the impact of colonization and other determinants of health.
Literature
1.
2.
Waldram JB, Herring DA, Young TK. Aboriginal health in Canada: historical, cultural, and epidemiological perspectives. 2nd ed. Toronto: University of Toronto Press; 2006.
3.
4.
5.
6.
7.
8.
Moore SP, Antoni S, Colquhoun A, et al. Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study. Lancet Oncol. 2015;16:1483–92.PubMedCrossRef
9.
10.
Young TK, Kliewer E, Blanchard J, Mayer T. Monitoring disease burden and preventative behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada. Am J Public Health. 2000;90:1466–8.PubMedPubMedCentralCrossRef
11.
12.
Alvi RA. Breast, cervical and colorectal cancer survival rates for northern Saskatchewan residents and first nations. Dissertation, University of Saskatchewan; 1999.
13.
Sheppard AJ, Chiarelli AM, Marrett LD, Mirea L, Nishri DE, Trudeau ME. Detection of later stage breast cancer in first nations women in Ontario, Canada. Can J Public Heal. 2010;101:101–5.CrossRef
14.
15.
16.
17.
18.
19.
20.
Cunningham J, Rumbold AR, Zhang X, Condon JR. Incidence, aetiology, and outcomes of cancer in indigenous peoples in Australia. Lancet Oncol. 2008;9:585–95.PubMedCrossRef
21.
22.
23.
Jeffreys M, Stevanovic V, Tobias M, Lewis C, Ellison-Loschmann L, Pearce N, Blakely T. Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Pub Health. 2005;95:834–7.CrossRef
24.
Obertova Z, Scott N, Brown C, Stewart A, Lawrenson R. Survival disparities between Maori and non-Maori men with prostate cancer in New Zealand. BJU Int. 2015;115:24–30.PubMedCrossRef
25.
Obertova Z, Lawrenson R, Scott N, et al. Treatment modalities for Maori and New Zealand European men with localised prostate cancer. Int J Clin Oncol. 2015;20:814–20.PubMedCrossRef
26.
Statistics Canada (2017) Canada [Country] and Canada [Country] (Table): Census Profile. Statistics Canada Catalogue No. 98–316-X2016001.
27.
Statistics Canada (2017) Manitoba [Province] and Canada [Country] (Table): Census Profile. Statistics Canada Catalogue No. 98–316-X2016001.
28.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef
29.
Edge SB, American Joint Committee on Cancer. AJCC Cancer staging manual. 7th ed. New York: Springer; 2010.CrossRef
30.
Vasilevska M, Ross SA, Gesink D, Fisman DN. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J Pub Hlth Pol. 2012;33:148–64 https://​doi.​org/​10.​1057/​jphp.​2012.​8.
31.
32.
MacDonald C, Martin-Misener R, Steenbeek A, Browne A. Honouring stories: Mi’kmaq women’s experiences with pap screening in eastern Canada. Can J Nrs Res. 2015;47:72–96.CrossRef
33.
34.
Black AT. Cervical cancer screening strategies for aboriginal women. Pimitisiwin. 2009;7:157–79.
35.
36.
37.
38.
39.
40.
41.
Hotson KE, Macdonald SM, Martin BD. Understanding death and dying in select first nations communities in northern Manitoba: issues of culture and remote service delivery in palliative care. Int J Circumpolar Health. 2004;63:25–38.PubMedCrossRef
42.
43.
44.
Minore B, Boone M, Katt M, Kinch P, Birch S, Mushquash C. The effects of nursing turnover on continuity of care in isolated first nation communities. Can J Nurs Res. 2005;37:86–100.PubMed
45.
46.
47.
Rosicki A. Understanding barriers and facilitators to breast cancer screening among urban first nations women. Dissertation, Simon Fraser University; 2010.
48.
49.
50.
51.
52.
53.
Jensen-Ross C. Cervical screening among southern Alberta first nations women living off-reserve. Dissertation, University of Lethbridge; 2006.
54.
55.
56.
Smylie J, Firestone M. the health of indigenous peoples. In: Raphael D, editor. Social determinants of health: Canadian perspectives. 2nd ed. Toronto: Canadian Scholars’ Press; 2016.
57.
Adelson N. The embodiment of inequity. Can J Pub Health. 2005;96(S2):S45–61.CrossRef
58.
59.
Metadata
Title
Comparing cancer incidence, stage at diagnosis and outcomes of First Nations and all other Manitobans: a retrospective analysis
Authors
Tara C. Horrill
Lindsey Dahl
Esther Sanderson
Garry Munro
Cindy Garson
Carole Taylor
Randy Fransoo
Genevieve Thompson
Catherine Cook
Janice Linton
Annette S. H. Schultz
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6296-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform

Study protocol

Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial

Research article

TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin

Research article

Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)

Study protocol

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

Research article

Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits